ANRO - Alto Neuroscience • Financials

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	0	-37	-	0%	L	-72	L	-73	-	-36	-0	68	-37	0	0	-	-
12/2024	0	-68	-	0%	L	151	L	-158	-	-55	-2	136	-57	0	0	-	-
12/2025	0	-66	-	0%	L	151	L	-160	-	-60	-0	60	-60	0	0	-	-

To see all financials—including updated, you must be Premium.